Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of BI 655064 in Healthy Chinese Male Volunteers (Randomised, Double-blind, Placebo-controlled, Clinical Phase I Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs BI 655064 (Primary)
- Indications Idiopathic thrombocytopenic purpura; Lupus nephritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Oct 2020 Prof. In-Jin Jang is the principal investigator as per the results published in in the British Journal of Clinical Pharmacology
- 13 Oct 2020 Results published in the British Journal of Clinical Pharmacology
- 31 May 2016 Status changed from active, no longer recruiting to completed.